Prevalence of inflammation in patients with cardiovascular disease and heart failure.
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Registration Number
- CTRI/2024/05/067153
- Lead Sponsor
- ovo Nordisk AS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.
2. Age 18 years or above at the time of signing the informed consent.
3. Presence of ASCVD and/or HF.
4. Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).
1. Previous participation in this study. Participation is defined as having given informed
consent in this study.
2. Current participation (i.e., signed informed consent) in any other interventional clinical
study.
3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of
chronic disease with hospitalization).
4. Clinical evidence, or suspicion of, active infection within the last 60 days.
5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding
or cooperation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate the prevalence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with ASCVD and/or HF, and subgroups hereof.Timepoint: Primary objective will be assessed during subject visit date and there is only one subject visit in this study.
- Secondary Outcome Measures
Name Time Method • To examine IL-6 stratified by the presence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with ASCVD and/or HF, & subgroups hereof. <br/ ><br>• To examine NT-proBNP stratified by the presence of systemic inflammation (defined as hsCRP =2 mg/L) in pre-defined cohorts of patients with HF, & subgroups hereof. <br/ ><br>Timepoint: Secondary objective will be assessed during subject visit date & there is only one subject visit in this study.